Investors Getting Picky When It Comes To Buying FibroGen Inc (FGEN)

FibroGen Inc (NASDAQ:FGEN) does about 2.53M shares in volume on a normal day but saw 3391224 shares change hands in Friday trading. The company now has a market cap of 71.78M USD. Its current market price is $0.72, marking an increase of 4.43% compared to the previous close of $0.69. The 52 week high reached by this stock is $3.02 whilst the lowest price level in 52 weeks is $0.33.

FibroGen Inc (FGEN) has a 20-day trading average at $1.0292 and the current price is -76.10% off the 52-week high compared with 116.50% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.1191 and its 200-day simple moving average is $1.1585. If we look at the stock’s price movements over the week, volatility stands at 13.17%, which decreases to 8.93% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 28.03 to suggest the stock is oversold.

The consensus objective for the share price is $1.50, suggesting that the stock has a potential upside of 52.0% over the period.


The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 08, 2023 when BofA Securities downgraded the stock to “Underperform” and issued a price target of between $4 and $2.

FibroGen Inc (FGEN) stock is down -29.94% over the week and -38.85% over the past month. Its price is -18.58% year-to-date and -74.32% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of -0.9 below consensus estimates by -0.2. The company’s next earnings report forecasts estimating quarterly EPS at -0.32 and -1.31 for whole year. Expected sales for next quarter are $33.64M, which analysts say will come at $150.41M for the current fiscal year and next year at $152.44M. In addition, estimates put the company’s current quarterly revenue at an average of $35.06M.

To reach the target analysts have set, the stock logically needs to grow 52.0 percent from here.

The company has a return on equity of -42790.17%. The beta has a value of 0.71. Price to sales ratio is 0.43.